Home > Insider Trading > Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Inc (ACAD)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
41 - 50
Next >>

Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...

Keep Reading →

October 24th, 2019 - Hedge Funds News

Hedge Fund and Insider Trading News: Ken Griffin, Tom Steyer, Amber Capital, Acadia Pharmaceuticals Inc. (ACAD), and More

PARIS (Reuters) - Activist shareholder Amber Capital, which is being sued by Lagardere (LAGA.PA), said on Monday the lawsuit was baseless and it would continue to seek strategy and management changes ...

Keep Reading →

October 14th, 2019 - Hedge Funds Insider Trading

Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?

Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies...

Keep Reading →

June 11th, 2019 - Hedge Funds News

Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?

Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.

Keep Reading →

April 29th, 2019 - Hedge Funds News

Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?

"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing.

Keep Reading →

December 16th, 2018 - Hedge Funds News

Hedge Fund and Insider Trading News: Crispin Odey, Third Point LLC, Criterion Capital, Twitter Inc (TWTR), ACADIA Pharmaceuticals Inc. (ACAD), and More

Crispin Odey, whose bearish bets led to his hedge fund suffering three successive years of losses, is firmly back on the rise. The Odey European Inc.

Keep Reading →

October 4th, 2018 - Hedge Funds Insider Trading

13D Filing: Baker Bros. Advisors and Acadia Pharmaceuticals Inc (NASDAQ:ACAD)

Baker Bros. Advisors purchased about 1.2 million shares of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) for about $19 per share last week.

Keep Reading →

September 24th, 2018 - Hedge Funds Insider Trading News

13D Filing: Baker Bros. Advisors and Acadia Pharmaceuticals Inc (ACAD)

Acadia Pharmaceuticals Inc (NASDAQ:ACAD): Julian Baker And Felix Baker's Baker Bros. Advisors filed an amended 13D. You can check out Baker Bros. Advisors' latest holdings and filings here. Please follow Baker Bros.

Keep Reading →

October 17th, 2017 - Hedge Funds